Patents Assigned to MAASTRO Clinic
-
Publication number: 20230146314Abstract: The invention relates to the radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject. In particular the invention relates to an endorectal probe device for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject. Furthermore the invention relates to an afterloading apparatus for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject using an endorectal probe device according to the invention. Moreover the invention relates to a method for effecting radiation treatment of colorectal cancerous tissue in the rectum of a human or animal subject, wherein the method implements the endorectal probe device according to the invention.Type: ApplicationFiled: October 17, 2022Publication date: May 11, 2023Applicants: UNiversiteit Maastricht, Academisch Ziekenhuis Maastricht, Stichting Maaastricht Radiation Oncology "Maastro-Clinic"Inventors: Frank VERHAEGEN, Murillo BELLEZZO, Evert VAN LIMBERGEN, Maaike BERBEE, Brigitte RENIERS, Gabriel PAIVA FONSECA
-
Publication number: 20160078613Abstract: The present invention relates to a decision support system and an image analysis method for providing information for enabling determination of a phenotype of a neoplasm in a human or animal body for enabling prognostication, comprising the steps of: receiving, by a processing unit, image data of the neoplasm; and deriving, by the processing unit, a plurality of image feature parameter values from the image data, said image parameter values relating to image features associated with the neoplasm; and deriving, by said processing unit using a signature model, one or more neoplasm signature model values associated with the neoplasm from said image feature parameter values, wherein said signature model includes a functional relation between or characteristic values of said image feature parameter values for deriving said neoplasm signature model valuesType: ApplicationFiled: April 17, 2014Publication date: March 17, 2016Applicant: Stichting Maastricht Radiation Oncology "Maastro-Clinic"Inventors: Philippe Lambin, Hugo Johannes Wilhelmus Louis Aerts
-
Publication number: 20150150849Abstract: The present invention concerns novel carbonic anhydrase IX inhibitors comprising a nitroimidazole moiety and their use in therapy of hypoxic conditions, in particular cancer treatment, especially chemotherapy and radiotherapy. The compounds of the invention have an increased specificity for the carbonic anhydrase IX enzyme compared to the art.Type: ApplicationFiled: February 4, 2015Publication date: June 4, 2015Applicants: STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO- CLINIC", UNIVERSITE MONTPELLIER 2 Sciences et TechniquesInventors: Philippe Lambin, Jean-Yves Winum, Claudiu Supuran
-
Publication number: 20130274305Abstract: The present invention concerns novel carbonic anhydrase IX inhibitors comprising a nitroimidazole moiety and their use in therapy of hypoxic conditions, in particular cancer treatment, especially chemotherapy and radiotherapy. The compounds of the invention have an increased specificity for the carbonic anhydrase IX enzyme compared to the art. The present invention relates to novel nitroimidazole derivates represented by formula (1).Type: ApplicationFiled: December 21, 2011Publication date: October 17, 2013Applicants: STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO-CLINIC", CNRS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Philippe Lambin, Jean-Yves Winum, Claudiu Supuran
-
Publication number: 20100057651Abstract: Knowledge-based interpretable predictive modeling is provided. Expert knowledge is used to seed training of a model by a machine. The expert knowledge may be incorporated as diagram information, which relates known causal relationships between predictive variables. A predictive model is trained. In one embodiment, the model operates even with a missing value for one or more variables by using the relationship between variables. For application, the model outputs a prediction, such as the likelihood of survival for two years of a lung cancer patient. A graphical representation of the model is also output. The graphical representation shows the variables and relationships between variables used to determine the prediction. The graphical representation is interpretable by a physician or other to assist in understanding.Type: ApplicationFiled: July 21, 2009Publication date: March 4, 2010Applicants: Siemens Medicals Solutions USA, Inc., MAASTRO clinicInventors: Glenn Fung, Cary Dehing-Oberije, Andreas Lubbertus Aloysius Johannes Dekker, Philippe Lambin, Shipeng Yu, Kartik Jayasurya Komati
-
Publication number: 20090234628Abstract: A system for modeling complete response prediction is provided. The system includes an input that is operable to receive treatment information representing treatment data that may be used to predict a complete response of a tumor. The complete response may include a disappearance of all or substantially all of a disease. A processor may be operable to use a model to predict complete response of the tumor as a function of the treatment data. The model represents a probability of complete response to treatment given the treatment data. A display is operable to output an image as a function of the complete response prediction.Type: ApplicationFiled: March 10, 2009Publication date: September 17, 2009Applicants: Siemens Medical Solutions USA, Inc., MAASTRO clinicInventors: Shipeng Yu, Glenn Fung, Cary Dehing-Oberije, Lucas Carolus Gertrudis Gerardus Persoon, Sriram Krishnan, R. Bharat Rao, Philippe Lambin, Ruud G.P.M. Van Stiphout, Jeroen Buijsen, Guido Lammering, Marco Janssen, Eric Postma, Vincenzo Valentini
-
Publication number: 20090234627Abstract: Modeling of prognosis of survivability, side-effect, or both is provided. For example, RILI is predicted using bullae information. The amount, volume or ratio of Bullae, even alone, may indicate the likelihood of complication, such as the likelihood of significant (e.g., stage 3) pneumonitis. As another example, RILI is predicted using uptake values of an imaging agent. Standardized uptake from a functional image (e.g., FDG uptake from a positron emission image), alone or in combination with other features, may indicate the likelihood of side-effect. In another example, survivability, such as two-year survivability, is predicted using blood biomarkers. The characteristics of a patient's blood may be measured and, alone or in combination with other features, may indicate the likelihood of survival. The modeling may be for survivability, side-effect, or both and may use one or more of the blood biomarker, uptake value, and bullae features.Type: ApplicationFiled: March 6, 2009Publication date: September 17, 2009Applicants: Siemens Medical Solutions USA, Inc., MAASTRO ClinicInventors: Shipeng Yu, Gelnn Fung, Cary Dehing-Oberije, Dirk de Ruysscher, Sriram Krishnan, R. Bharat Rao, Philippe Lambin